Puma Biotechnology Stock (NASDAQ:PBYI), Trade Ideas

Puma Biotechnology

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

News

Penny Stocks

Pre-Market Outlook

Markets

Movers

Trading Ideas

ABVC

ALPS

AULT

BRFS

COSM

DYNT

JXJT

NBTX

NCPL

NFLX

PBYI

PRFX

RELL

SYBX

TSLA

TTOO

Gainers


	Lytus Technologies Holdings PTV. Ltd. (NASDAQ: LYT) shares surged 39.3% to $0.6621 in pre-market trading after gaining around 14% on Wednesday.


Why Nanobiotix Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket

Small Cap

Intraday Update

ANGO

ARCT

AXDX

BBBY

BOXD

BSFC

BTTX

CAAS

CDAK

CFMS

CYXT

CZOO

DFLI

EOSE

EVGO

FLNC

FXLV

GMVD

JEWL

LASE

LGMK

LITB

MCLD

MULN

NAAS

NCMI

PALI

PHAT

PRQR

REVE

RNXT

SCYX

SGBX

SMTC

SNDA

TORO

TRMD

VRNT

Gainers


	SCYNEXIS, Inc. (NASDAQ: SCYX) shares climbed 68% to $2.8184 after the company announced an exclusive license agreement with GSK for Brexafemme, in which the company will receive an upfront payment of $90 million.


Why Bed Bath &amp; Beyond Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

ADMP

ANGH

ARDX

BBAI

BFRG

BMRA

CDNA

CDTX

COMP

CYTO

DESP

DMTK

EGLE

ETAO

GNLX

GSX Techedu Inc. American Depositary Shares

GOTU

HILS

HRTG

HUBC

IONM

KUKE

LHDX

LPSN

LSDI

LVRO

LXRX

MRVL

NPCE

OBSV

PAGS

PRAX

PTRA

RDIB

RKDA

RUBY

SECO

SEER

VERI

VERU

XPOF

ZLAB

Gainers


	ObsEva SA (NASDAQ: OBSV) surged 86.6% to $0.1978 after dropping over 12% on Thursday. ObsEva recently announced strategic reorganization to consolidate operations in Switzerland.


Why Puma Biotechnology Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Puma Biotechnology Inc

Biotech

General

Puma Biotechnology Announces FDA Allowance To Proceed Under IND For Alisertib In HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBYI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$5.00</td>
<td>$49.3K</td>
<td>147</td>
<td>5.1K</td>
</tr>
<tr>
<td>ACAD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$20.00</td>
<td>$160.0K</td>
<td>1.0K</td>
<td>4.1K</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$82.50</td>
<td>$59.5K</td>
<td>6.0K</td>
<td>795</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$240.00</td>
<td>$90.0K</td>
<td>6</td>
<td>690</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$125.00</td>
<td>$192.5K</td>
<td>62</td>
<td>649</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$950.00</td>
<td>$92.6K</td>
<td>149</td>
<td>517</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/28/24</td>
<td>$180.00</td>
<td>$31.0K</td>
<td>865</td>
<td>444</td>
</tr>
<tr>
<td>IOVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$10.00</td>
<td>$32.0K</td>
<td>4.1K</td>
<td>151</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$75.00</td>
<td>$251.6K</td>
<td>2.1K</td>
<td>124</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$165.00</td>
<td>$36.6K</td>
<td>541</td>
<td>123</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For PBYI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBYI#NASDAQ">PBYI</a>), we notice a call option trade that happens to be bearish, expiring in 31 day(s) on April 19, 2024. This event was a transfer of 4939 contract(s) at a $5.00 strike. The total cost received by the writing party (or parties) was $49.3K, with a price of $10.0 per contract. There were 147 open contracts at this strike prior to today, and today 5131 contract(s) were bought and sold. 
• For ACAD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>), we notice a call option trade that happens to be bearish, expiring in 31 day(s) on April 19, 2024. This event was a transfer of 4000 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $160.0K, with a price of $40.0 per contract. There were 1092 open contracts at this strike prior to today, and today 4101 contract(s) were bought and sold. 
• Regarding CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we observe a call option sweep with bearish sentiment. It expires in 59 day(s) on May 17, 2024. Parties traded 402 contract(s) at a $82.50 strike. This particular call needed to be split into 16 different trades to become filled. The total cost received by the writing party (or parties) was $59.5K, with a price of $148.0 per contract. There were 6034 open contracts at this strike prior to today, and today 795 contract(s) were bought and sold. 
• For BIIB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>), we notice a call option sweep that happens to be bullish, expiring in 59 day(s) on May 17, 2024. This event was a transfer of 250 contract(s) at a $240.00 strike. This particular call needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $90.0K, with a price of $359.0 per contract. There were 6 open contracts at this strike prior to today, and today 690 contract(s) were bought and sold. 
• For NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we notice a put option sweep that happens to be bullish, expiring in 59 day(s) on May 17, 2024. This event was a transfer of 500 contract(s) at a $125.00 strike. This particular put needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $192.5K, with a price of $385.0 per contract. There were 62 open contracts at this strike prior to today, and today 649 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option sweep with bullish sentiment. It expires in 59 day(s) on May 17, 2024. Parties traded 241 contract(s) at a $950.00 strike. This particular call needed to be split into 33 different trades to become filled. The total cost received by the writing party (or parties) was $92.6K, with a price of $385.0 per contract. There were 149 open contracts at this strike prior to today, and today 517 contract(s) were bought and sold. 
• For ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we notice a call option sweep that happens to be bearish, expiring in 9 day(s) on March 28, 2024. This event was a transfer of 200 contract(s) at a $180.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $31.0K, with a price of $155.0 per contract. There were 865 open contracts at this strike prior to today, and today 444 contract(s) were bought and sold. 
• For IOVA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>), we notice a call option sweep that happens to be bullish, expiring in 304 day(s) on January 17, 2025. This event was a transfer of 50 contract(s) at a $10.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $32.0K, with a price of $640.0 per contract. There were 4196 open contracts at this strike prior to today, and today 151 contract(s) were bought and sold. 
• Regarding VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we observe a call option trade with bearish sentiment. It expires in 31 day(s) on April 19, 2024. Parties traded 296 contract(s) at a $75.00 strike. The total cost received by the writing party (or parties) was $251.6K, with a price of $850.0 per contract. There were 2118 open contracts at this strike prior to today, and today 124 contract(s) were bought and sold. 
• Regarding JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we observe a call option trade with bullish sentiment. It expires in 185 day(s) on September 20, 2024. Parties traded 100 contract(s) at a $165.00 strike. The total cost received by the writing party (or parties) was $36.6K, with a price of $366.0 per contract. There were 541 open contracts at this strike prior to today, and today 123 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ABBV

ACAD

BIIB

IOVA

VKTX

10 Health Care Stocks With Whale Alerts In Today's Session

Rumors

Legal

Watching Puma Biotechnology; Traders Circulate Rumor, "Puma Has Been Dismissed As A Plaintiff In Its Case Against AstraZeneca Alleging That Tagrisso Infringes Its Patents Citing Lack Of Standing"

HC Wainwright &amp; Co. analyst Edward White maintains Puma Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBYI#NASDAQ">PBYI</a>) with a Buy and lowers the price target from $8 to $7.

Price Target

Analyst Ratings

HC Wainwright & Co. Maintains Buy on Puma Biotechnology, Lowers Price Target to $7

Guidance

Puma Biotechnology Sees FY24 Net Product Revenue $183M-$190M

Puma Biotechnology Sees Q1 2024 Net Product Revenue $38M-$40M

WIIM

Puma Biotechnology shares are trading lower after the company reported mixed Q4 financial results.

Puma Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBYI#NASDAQ">PBYI</a>) reported quarterly earnings of $0.310 per share which beat the analyst consensus estimate of $0.300 by 3.33 percent. The company reported quarterly sales of $72.200 million which missed the analyst consensus estimate of $73.550 million by 1.84 percent. This is a 9.89 percent increase over sales of $65.700 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Puma Biotechnology Q4 2023 Adj EPS $0.310 Beats $0.300 Estimate, Sales $72.200M Miss $73.550M Estimate

<h3>Gainers</h3>
<ul>
<li>Cogent Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COGT#NASDAQ">COGT</a>) stock increased by 64.0% to $8.96 during Wednesday's regular session. The company's market cap stands at $771.2 million. </li>
<li>Larimar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRMR#NASDAQ">LRMR</a>) shares increased by 45.53% to $12.72. The company's market cap stands at $558.4 million. </li>
<li>BioXcel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTAI#NASDAQ">BTAI</a>) stock rose 35.2% to $3.33. The company's market cap stands at $101.0 million. </li>
<li>Greenwich LifeSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLSI#NASDAQ">GLSI</a>) stock moved upwards by 31.26% to $10.91. The company's market cap stands at $140.1 million. </li>
<li>Electromed (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ELMD#AMEX">ELMD</a>) stock rose 22.61% to $12.43. The market value of their outstanding shares is at $106.6 million. As per the news, the Q2 earnings report came out yesterday. </li>
<li>Puma Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBYI#NASDAQ">PBYI</a>) shares moved upwards by 18.76% to $7.38. The market value of their outstanding shares is at $350.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Anitra (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#AMEX">AZTR</a>) stock declined by 71.3% to $0.25 during Wednesday's regular session. The market value of their outstanding shares is at $3.0 million. </li>
<li>QuidelOrtho (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) stock fell 29.1% to $47.34. The company's market cap stands at $3.1 billion. As per the news, the Q4 earnings report came out yesterday. </li>
<li>NeuroOne Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>) shares decreased by 16.35% to $1.18. The company's market cap stands at $30.5 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Renalytix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNLX#NASDAQ">RNLX</a>) shares fell 14.9% to $1.2. The company's market cap stands at $59.9 million. </li>
<li>Sientra (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIEN#NASDAQ">SIEN</a>) shares declined by 14.22% to $0.17. The company's market cap stands at $2.0 million. </li>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) shares declined by 12.51% to $0.06. The company's market cap stands at $1.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AZTR

BTAI

COGT

ELMD

GLSI

Larimar Therapeutics, Inc. - Common Stock

LRMR

NMTC

QDEL

RNLX

SBFM

SIEN

12 Health Care Stocks Moving In Wednesday's Intraday Session

HC Wainwright &amp; Co. analyst Edward White reiterates Puma Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBYI#NASDAQ">PBYI</a>) with a Buy and maintains $8 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Puma Biotechnology, Maintains $8 Price Target

Puma Biotechnology Initiates ALISCA-Lung1 Phase II Trial Of Alisertib In Small Cell Lung Cancer

Patients will be dosed with alisertib given at either 30 mg, 40 mg or 50 mg twice daily (BID) on days 1-3, 8-10 and 15-17 on a 28-day cycle in combination with the endocrine therapy of the investigator's choice. Patients must not have been previously treated with the endocrine treatment that will be given in combination with alisertib in the trial. Each dose level will enroll up to 50 patients. Patients must provide blood samples and tissue-based biopsies so that biomarkers can be evaluated. The primary efficacy end points will include objective response rate (ORR), duration of response (DOR), disease control rate (DCR) and progression-free survival (PFS). As a secondary objective, the Company will be evaluating each of these efficacy endpoints within biomarker subgroups in order to determine whether any biomarker subgroup correlates with better efficacy as has been seen in preclinical and clinical studies in other cancers including breast cancer and small cell lung cancer. The Company will then look to focus the future clinical development of alisertib in combination with endocrine therapy for patients with HER2-negative hormone receptor-positive breast cancer in patients with these biomarkers.

Puma Biotechnology Announces Phase II Clinical Trial Design For Alisertib In HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer; Plans To Initiate Trial In H2 2024

Michael P. Miller, Board Member at Puma Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBYI#NASDAQ">PBYI</a>), reported a large insider sell on November 9, according to a new SEC filing. 
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001401667/000143774923031275//Archives/edgar/data/1401667/000143774923031275/0001437749-23-031275-index.htm">U.S. Securities and Exchange Commission</a> on Thursday showed that Miller sold 25,000 shares of Puma Biotechnology. The total transaction amounted to $70,802. 
Puma Biotechnology shares are trading down 0.3% at $3.3 at the time of this writing on Friday morning.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Important Transaction Codes</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates the insider may have been forced to sell shares in order to receive compensation that had been promised upon being hired by the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001401667">Check Out The Full List Of Puma Biotechnology's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Puma Biotechnology Board Member Trades Company's Stock

Puma Biotechnology Sees FY23 Revenue $206M-$209M Vs $236.23M Est

Puma Biotechnology Sees Q4 2023 Product Revenue $56M-$59M Vs $71.45M Est

Puma Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBYI#NASDAQ">PBYI</a>) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $0.08 by 112.5 percent. This is a 240 percent increase over earnings of $0.05 per share from the same period last year. The company reported quarterly sales of $56.10 million which missed the analyst consensus estimate of $57.95 million by 3.19 percent. This is a 1.75 percent decrease over sales of $57.10 million the same period last year.

Puma Biotechnology Q3 2023 Adj EPS $0.17 Beats $0.08 Estimate, Sales $56.10M Miss $57.95M Estimate

Puma Biotechnology Presented Findings From A Phase I/II Study Of Alisertib And Pembrolizumab For Rb-Deficient Head And Neck Squamous Cell Carcinomas At The 2023 AACR-NCI-EORTC Molecular Targets And Cancer Therapeutics Meeting

Puma Biotechnology Secures FDA Orphan Drug Designation For Alisertib For The Treatment Of Small Cell Lung Cancer

Puma Biotechnology Announces FDA Clearance Of IND For Alisertib In Small Cell Lung Cancer

With advances in gene therapy and personalized medicine, growing applications in agriculture and industrial processes, government support, and convergence of technologies, the biotechnology industry holds solid growth potential. Thus, biotech stocks United Therapeutics (UTHR), Puma Biotechnology (PBYI), and Genmab (GMAB) could be ideal investments for future returns. Read more… Key trends, including advancements in gene editing technologies with the introduction of CRISPR-Cas9, the development of personalized medicines, rising applications in agriculture and industrial processing, the surge of synthetic biology, and supportive government funding and incentives, will shape the biotech industry this year and beyond.
Given the industry tailwinds, it could be wise to invest in fundamentally sound biotech stocks United Therapeutics Corporation (<a href="https://stocknews.com/stock/UTHR/">UTHR</a>), Puma Biotechnology, Inc. (<a href="https://stocknews.com/stock/PBYI/">PBYI</a>), and Genmab A/S (<a href="https://stocknews.com/stock/GMAB/">GMAB</a>) for future solid returns.
The biotechnology industry continues to foster significant developments in healthcare, agriculture, and industrial processes. The industry is transforming healthcare by enabling personalized medicine, gene therapy, and regenerative medicine. The pharma sector also uses biotechnology to accelerate drug discovery and development processes.
From biofuels to bioplastics, biotechnology is accelerating the development of sustainable alternatives to traditional fossil fuels and plastics. In addition, there are growing applications of biotech in agriculture, as it has improved crop yield, lowered dependency on chemical pesticides, and developed crops with increased nutritional value.
According to the Transparency Market Research report, the <a href="https://www.globenewswire.com/en/news-release/2024/01/19/2812379/32656/en/Agricultural-Biotechnology-Market-Projected-to-Reach-USD-64-7-billion-with-Advancing-CAGR-of-9-5-by-2031-Transparency-Market-Research-Inc.html">agricultural biotechnology market</a> is expected to reach $64.70 billion by 2031, growing at a CAGR of 9.5%. Several factors, like the growing need to increase food production, the demand for sustainable agriculture, and the rapidly rising global population, will drive the market's growth.
Overall, the global biotechnology market is projected to reach $3.88 trillion by 2030, <a href="https://www.grandviewresearch.com/industry-analysis/biotechnology-market#:~:text=The%20global%20biotechnology%20market%20is,USD%203.88%20trillion%20by%202030.">expanding at a CAGR of 14%</a> from 2024 to 2030. The market growth is driven by government initiatives emphasizing the modernization of regulatory framework, improvements in approval processes &amp; reimbursement policies, and standardization of clinical studies.
The biotechnology market's potential to revolutionize everyday life, with scientists and researchers using it to make rapid advances in medical treatment, genetic engineering in agriculture and novel biomaterials, has <a href="https://www.usnews.com/news/politics/articles/2024-02-19/us-rivalry-with-china-expands-to-biotech-lawmakers-see-a-failure-to-compete-and-want-to-act">caught the attention of both the Chinese and U.S. governments</a>, driving innovations and growth opportunities.
That also led to the Biden administration putting forth a "whole-of-government approach" to enhance biotechnology and biomanufacturing, which are crucial for health, climate change, energy, food security, agriculture, and supply chain resilience.
Also, in today's dynamic landscape of <a href="https://datahorizzonresearch.com/artificial-intelligence-in-biotechnology-market-2333">technological advancements</a>, the biotechnology market stands at the forefront, projecting a plethora of top trends. One such trend is the integration of artificial intelligence (AI) and machine learning (ML) in biotechnological research and development.
Investors' interest in biotech stocks is evident from the SPDR Series Trust SPDR S&amp;P Biotech ETF (<a href="https://stocknews.com/stock/XBI/">XBI</a>) 21.3% returns over the past six months.
With these encouraging trends in mind, let's delve into the fundamentals of the three <a href="https://stocknews.com/category/biotech/">Biotech</a> stock picks, beginning with the third choice.
Stock #3: Genmab A/S (<a href="https://stocknews.com/stock/GMAB/">GMAB</a>)
Headquartered in Copenhagen, Denmark, GMAB develops antibody therapeutics for the treatment of cancer and other diseases, primarily in Denmark. The company markets DARZALEX, teprotumumab, and Amivantamab.
On February 27, 2024, GMAB announced that the U.S. FDA granted Priority Review for the supplemental Biologics License Application (sBLA) for epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneously, for treating adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy.
sBLA submission reflects GMAB's commitment to exploring the potential utility of epcoritamab across B-cell malignancies.
During the fourth quarter of 2023, GMAB announced that the EMA validated for review a Type II variation application for epcoritamab as monotherapy for the treatment of adult patients with relapsed or refractory FL after two or more lines of systemic therapy. Data from the FL cohort of the EPCORE NHL-1 trial supported the application.
In terms of forward non-GAAP PEG, GMAB is trading at 1.30x, 33.5% lower than the industry average of 1.95x. Likewise, the stock's forward EV/EBIT multiple of 15.79 is 2.2% lower than the industry average of 16.15.
GMAB's trailing-12-month gross profit margin and <a href="https://www.investopedia.com/terms/e/ebitda-margin.asp#:~:text=The%20Bottom%20Line-,EBITDA%20stands%20for%20earnings%20before%20interest%2C%20taxes%2C%20depreciation%2C%20and,dividing%20EBITDA%20by%20total%20revenue.">EBITDA margin</a> of 98.63% and 33.76% are 71.6% and 515.8% higher than the respective industry averages of 57.46% and 5.48%. Also, the stock's trailing-12-month asset turnover ratio of 0.50x is 28.2% higher than the industry average of 0.39x.
For the fiscal year 2023, which ended December 31, 2023, GMAB's revenue increased 13.6% year-over-year to DKK 16.47 billion ($2.39 billion), and its operating profit for the year was DKK 5.32 billion ($772.80 million). The company's net profit came in at DKK 4.35 billion ($632.07 million) and DKK 66.02 per share, respectively.
In addition, as of December 31, 2023, the company's total assets stood at DKK 35.29 billion ($5.12 billion), compared to DKK 30.12 billion ($4.37 billion) as of December 31, 2022.
As per the fiscal year 2024 outlook, GMAB expects revenue between DKK 18.70 billion ($2.71 billion) and DKK 20.50 billion ($2.98 billion). And its gross profit is expected to range from DKK 18 billion ($2.61 billion) to DKK 19.50 billion ($2.83 billion).
Analysts expect GMAB's revenue and EPS for the first quarter (ending March 2024) to increase 37.9% and 306.7% year-over-year to $580.33 million and $0.21, respectively. Also, the company has surpassed the consensus revenue estimates in each of the trailing four quarters.
Shares of GMAB have surged marginally over the past month to close the last trading session at $27.77.
GMAB's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect its robust outlook. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
GMAB has a B grade for Quality and Value. It is ranked #13 out of 360 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry.
In addition to the POWR Ratings we've stated above, we also have GMAB's ratings for Sentiment, Momentum, Stability, and Growth. Get all GMAB ratings <a href="https://stocknews.com/stock/GMAB/">here</a>.
Stock #2: Puma Biotechnology, Inc. (<a href="https://stocknews.com/stock/PBYI/">PBYI</a>)
PBYI is a biopharmaceutical company that engages in the development and commercialization of products to enhance cancer care globally. Its drug candidates include PB272 (neratinib, oral). Its product portfolio also comprises PB272 (neratinib, intravenous) and PB357.
On February 13, 2024, PBYI announced the initiation of its ALISertib in CAncer (ALISCA-Lung1) Phase II trial of alisertib monotherapy for the treatment of patients with extensive stage small cell lung cancer.
"We are pleased to initiate this Phase II trial, and we hope that the study will provide much needed insight into the clinical activity of alisertib in small cell lung cancer and, more specifically, in patients with molecularly defined tumors that may be targetable with an aurora kinase A inhibitor like alisertib," said Alan H. Auerbach, Chief Executive Officer, President and Founder of PBYI.
Also, on September 21, 2023, PBYI announced that the U.S. FDA granted Orphan Drug Designation to alisertib, a selective, small-molecule, orally administered inhibitor of aurora kinase A, for the treatment of patients with small cell lung cancer (SCLC).
In terms of forward Price/Sales, PBYI is trading at 1.30x, 67.8% lower than the industry average of 4.03x. Further, the stock's forward EV/EBIT multiple of 9.48 is 41.3% lower than the industry average of 16.1. Likewise, its forward non-GAAP P/E of 8.79x is 55.7% lower than the industry average of 19.85x.
During the fourth quarter that ended December 31, 2023, PBYI's total revenue increased 9.9% year-over-year to $72.20 million. The company's income from operations was $14.80 million, up 48% from the previous year's quarter.
Further, the company's non-GAAP adjusted net income came in at $14.80 million, or $0.31 per share, compared to a non-GAAP adjusted net loss of $3.0 million or $0.07 per share for the fourth quarter of 2022, respectively. Its cash and cash equivalents stood at $84.60 million as of December 31, 2023, versus $76.20 million as of December 31, 2022.
As per the financial outlook, PBYI expects net product revenue between $38 - $40 million for the first quarter and $183 - $190 million for the full year 2024. Also, its net income for the full year is estimated to range between $12 and $15 million.
Street expects PBYI's revenue for the second quarter (ending June 2024) to grow 11.7% year-over-year to $61 million, and its EPS is estimated to increase 40% year-over-year to $0.07. Additionally, PBYI topped the consensus EPS estimates in three of the trailing four quarters.
Over the past six months, PBYI's stock has gained 68.1% and 61.1% over the past year to close the last trading session at $6.22.
PBYI's sound fundamentals are reflected in its POWR Ratings. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
The stock has an A grade for Value and a B for Growth and Quality. Within the Biotech industry, PBYI is ranked #10 of 360 stocks.
<a href="https://stocknews.com/stock/PBYI/">Click here</a> to access additional ratings of PBYI for Momentum, Sentiment, and Stability.
Stock #1: United Therapeutics Corporation (<a href="https://stocknews.com/stock/UTHR/">UTHR</a>)
UTHR is a biotechnology company engaged in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases internationally. It offers Tyvaso DPI, Tyvaso, Remodulin (treprostinil) injection, Orenitram, and Adcirca.
On December 13, 2023, UTHR, through its wholly-owned subsidiary, Morpheus Subsidiary Inc., acquired all outstanding shares of Miromatrix Medical Inc. (<a href="https://stocknews.com/stock/MIRO/">MIRO</a>) for a purchase price of $3.25 per share in cash at closing and an additional $1.75 per share in cash.
This was upon the achievement of a clinical development milestone related to Miromatrix's development-stage, fully-implantable manufactured kidney product known as mirokidney&#x2122; by December 31, 2025. The acquisition aligns with the company's future objectives.
On September 22, UTHR announced the achievement of two milestones for its xenotransplantation programs. These milestones were the second transplant of a UHeart&#x2122; xenoheart into a living person and a 61-day study of the UThymoKidney&#x2122; xenokidney and thymus in a human pre-clinical model.
In terms of forward non-GAAP P/E, UTHR is trading at 9.30x, 52.8% lower than the industry average of 19.68x. Also, the stock's forward EV/Sales multiple of 2.43 is 36.5% lower than the industry average of 3.82. Further, its forward Price/Cash Flow of 9.65x is lower than the industry average of 15.74x.
UTHR's total revenues increased 25.1% year-over-year to $614.70 million for the fourth quarter, which ended December 31, 2023. Its operating income grew 48.1% from the year-ago value to $260.10 million. The company's net income came in at $217.10 million, or $4.36 per share, up 64.3% and 63.3% from the previous year's period, respectively.
As of December 31, 2023, the company's cash, cash equivalents and marketable investments were $4.90 billion, compared to $4.15 billion as of December 31, 2022.
Analysts expect UTHR's revenue for the first quarter (ending March 2024) to increase 23.5% year-over-year to $625.91 million. The consensus EPS estimate for the ongoing quarter of $5.61 indicates a 15.4% year-over-year growth. Moreover, UTHR surpassed the consensus EPS estimates in all four trailing quarters.
UTHR's stock has surged 4.4% over the past month to close the last trading session at $225.64.
UTHR's POWR Ratings reflect its bright prospects. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
UTHR has an A grade for Value and a B for Sentiment and Quality. It is ranked #7 among 360 stocks in the Biotech industry.
To access UTHR's ratings (Growth, Stability, and Momentum), <a href="https://stocknews.com/stock/UTHR/">click here</a>.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>

<hr />
GMAB shares rose $0.54 (+1.94%) in premarket trading Friday. Year-to-date, GMAB has declined -12.78%, versus a 6.89% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Mangeet Kaur Bouns</h2> <img src='https:/wp-content/uploads/2022/01/Mangeet-Kaur-Bouns_Image-4.jpg' style="float:left; padding:5px;width:125px;">Mangeet's keen interest in the stock market led her to become an investment researcher and financial journalist. Using her fundamental approach to analyzing stocks, Mangeet's looks to help retail investors understand the underlying factors before making investment decisions.<a href="https://stocknews.com/authors/?author=mangeet-kaurbouns">More...</a>The post <a href=https://stocknews.com/news/gmab-uthr-pbyi-miro-bank-on-the-future-returns-with-these-3-biotech-stocks/>Bank on the Future Returns With These 3 Biotech Stocks</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Bank on the Future Returns With These 3 Biotech Stocks

Puma Biotechnology dips after dismissal of its suit was granted by a federal judge

COIN, HUT and WNW among pre-market losers

The market has been down on Puma Biotechnology Inc (PBYI)  stock recently. PBYI gets a Bearish score from InvestorsObserver Stock Sentiment Indicator. Puma Biotechnology Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on PBYI!See Full PBYI ReportWhat is Stock Sentiment

Should You Buy Puma Biotechnology Inc (PBYI) Stock After it Has Fallen 18.13% in a Week?

Puma Biotech cleared to trial Takeda-partnered breast cancer therapy in U.S.

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
If you&rsquo;re searching for stocks under $15, look no further. These seven offerings, all priced below $15, present a unique opportunity for individual investors to profit from future development. These equities cover various industries, from cutting-edge science and financial services to booming energy production and development opportunities, offering a diverse portfolio for potential profit.



The first one achieved an increasing market reach and improved financial stability through a deliberate change towards income diversification. Similarly, the latter can continue to profit even in the face of inflation. These stocks are resilient to market fluctuations, providing a secure investment option. Potential advances in the field of healthcare are indicated by the third one&rsquo;s progress in clinical trials for the treatment of depression and social anxiety.



In the meantime, the fourth technology company&rsquo;s success with connected TV (CTV) advertising highlights its capacity to adjust to changing market conditions. Additionally, the fifth one shows a dedication to sustainable expansion by optimizing operational performance.



Next, the sixth one&rsquo;s steadily increasing earnings from royalties and flagship items highlight its place in the market and steadiness. Finally, the energy sector&rsquo;s solid production increase in the seventh demonstrates how well it can access profitable hydrocarbon sources.



<h2>Stocks Under $15: SoFi (SOFI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/03/sofi1600-3-300x169.png" alt="SoFi logo sign on headquarters facade. Social Finance is an online personal finance company."><div>Source: Michael Vi / Shutterstock.com</div></div>By effectively diversifying its top-line, SoFi (NASDAQ:<a href="https://investorplace.com/stock-quotes/sofi-stock-quote/">SOFI</a>) has increased its target market and decreased its need in the lending segment. Thus, non-lending sectors increased their share of adjusted net revenue from&nbsp;<a href="https://s27.q4cdn.com/749715820/files/doc_financials/2023/q4/SoFi-Q4-2023-Earnings-Release.pdf" target="_blank">34% to 40%</a>&nbsp;in Q4 2023. 



Additionally, the Financial Services division had exceptional growth, with net sales rising to $139.1 million, an increase of 115% over the previous year. In addition, the technology platform business showed consistent growth, as seen by a<a href="https://s27.q4cdn.com/749715820/files/doc_financials/2023/q4/SoFi-Q4-2023-Earnings-Release.pdf" target="_blank">&nbsp;13% boost in net sales</a>&nbsp;over the prior year. These developments indicate SoFi&rsquo;s capacity to seize chances outside of the conventional loan space and use its platforms for financial services and technology to boost income.



Moreover, by reducing SoFi&rsquo;s exposure to the risks associated with any one product or market, income stream diversification improves the company&rsquo;s consolidated financial stability and resilience. Hence, by going beyond loans, SoFi will be able to reach a broader spectrum of consumer demands and enter new market sectors, opening up new growth prospects. 



<h2>CompoSecure (CMPO)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/01/creditcards1600-300x169.jpg" alt="a pile of credit cards, credit card interest rates"><div>Source: Teerasak Ladnongkhun/Shutterstock.com</div></div>CompoSecure (NASDAQ:<a href="https://investorplace.com/stock-quotes/cmpo-stock-quote/">CMPO</a>) has reported a pattern of increasing bottom-line. This reflects net income and adjusted EBITDA boosts attained under obstacles such as fluctuations in fair value obligations and inflationary pressure. Comparing Q4 2023 against Q4 2022, net income<a href="https://ir.composecure.com/news-releases/news-release-details/composecure-reports-fourth-quarter-and-full-year-2023-financial" target="_blank">&nbsp;increased by 39%</a>.&nbsp;



Indeed, reductions in expenditures, with other conservative operational expense management, led to this gain in the bottom line. Net income was also positively impacted by adjustments to the earnout consideration liability, derivative liability, and warrant liabilities&rsquo; fair values. Similarly, adjusted EBITDA&nbsp;<a href="https://ir.composecure.com/news-releases/news-release-details/composecure-reports-fourth-quarter-and-full-year-2023-financial" target="_blank">increased considerably</a>&nbsp;over the year. The company has focused on increasing its operational edge and boosting its bottom line. This is observed in the increase generated by net sales growth and operating expenditure reductions.



Overall, CompoSecure showed its adaptability and success in challenging market conditions by boosting adjusted EBITDA despite obstacles like&nbsp;<a target="_blank" href="https://finance.yahoo.com/news/composecure-inc-nasdaq-cmpo-q4-160013352.html">inflationary pressure</a>.



<h2>Stocks Under $15: Vistagen (VTGN)</h2>



<a href="https://investorplace.com/wp-content/uploads/2024/02/vtgn-vistagen.png"><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/02/vtgn-vistagen-300x169.png" alt="The logo for VistaGen Therapeutics, Inc (VTGN) is seen on a white background."></a>One of the main factors influencing Vistagen&rsquo;s (NASDAQ:<a href="https://investorplace.com/stock-quotes/vtgn-stock-quote/">VTGN</a>) growth potential is the <a href="https://www.vistagen.com/news-releases/news-release-details/vistagen-reports-fiscal-2024-third-quarter-financial-results-and" target="_blank">PALISADE Phase 3 program</a>. This focuses on developing fasedienol specifically for the acute treatment of social anxiety disorder (SAD). The PALISADE-3 trial may begin in H1 2024, and the PALISADE-4 trial may begin in H2 2024. These schedules show essential turning points in the organization&rsquo;s clinical development process.



Furthermore, the purpose of the multicenter, randomized, double-blind, placebo-controlled PALISADE studies is to assess the safety, tolerability, and&nbsp;<a href="https://finance.yahoo.com/news/vistagen-therapeutics-inc-nasdaq-vtgn-132008646.html" target="_blank">effectiveness of fasedienol</a>&nbsp;in adult patients with SAD. The trials are conducted in the United States and use the Subjective Units of Distress Scale (SUDS) as the primary efficacy objective to evaluate how well fasedienol relieves anxiety symptoms following a single dosage during a public speaking challenge.



Apart from fasedienol, Vistagen is also promoting the development of itruvone for the treatment of major depressive disorder (MDD) and PH80 for indications related to women&rsquo;s health. Planning and preparations are in place for Itruvone&rsquo;s&nbsp;<a href="https://www.vistagen.com/static-files/b1bcf087-576a-4e58-bd6c-4f5cdd9ad907" target="_blank">Phase 2B development for MDD</a>. In short, this suggests that Vistagen is strategically expanding its pipeline to target depression.



<h2>Viant (DSP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/03/digital-advertising-1600-300x169.jpg" alt="Close up hand holding mobile with Digital Advertising and icons, Digital Marketing concept. digital ad stocks"><div>Source: weedezign via Shutterstock</div></div>Viant (NASDAQ:<a href="https://investorplace.com/stock-quotes/dsp-stock-quote/">DSP</a>) has cutting-edge technological solutions and tactical efforts like Direct Access. This has proven to be a formidable force in the CTV advertising market. CTV is the company&rsquo;s biggest channel. In the fourth quarter of 2023, it accounted for about&nbsp;<a href="https://investors.viantinc.com/news-releases/news-release-details/viant-technology-announces-fourth-quarter-and-full-year-2023" target="_blank">40% of all ad expenditures</a>&nbsp;on Viant&rsquo;s platform. Viant&rsquo;s Household ID technology addresses the issues raised by the deprecation of cookies. This allows targeted advertising in cookie-free contexts, which is a major factor in this boost in ad expenditures.



Moreover, Viant&rsquo;s clientele and spending volumes have increased considerably, especially with larger mid-market clients. The number of clients making above $1 million in contributions in 2023 <a href="https://investors.viantinc.com/news-releases/news-release-details/viant-technology-announces-fourth-quarter-and-full-year-2023" target="_blank">rose by over 20%</a>&nbsp;compared to 2022. Furthermore, there were more than&nbsp;<a href="https://investors.viantinc.com/static-files/f8229159-9a45-44af-a22a-d0d7c81cf0e2" target="_blank">30% more clients</a>&nbsp;with over $500K in contributions than there were a year before.



To sum up, these patterns suggest Viant&rsquo;s ability to draw in and cater to larger clients with considerable advertising expenditures. Viant has increased its market reach and strengthened its ties with important clients by concentrating on the mid-market area and providing customized solutions that satisfy their demands.



<h2>Stocks Under $15: SNDL (SNDL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/sndl-1600-300x169.png" alt="The Sundial Growers logo is on a phone screen with a light blue background in front of the sundial logo on a white background. SNDL stock"><div>Source: Shutterstock</div></div>In 2023, with an operating loss of&nbsp;<a href="https://s201.q4cdn.com/372870431/files/doc_news/SNDL-Reports-Full-Year-and-Fourth-Quarter-2023-Financial-and-Operational-Results-2024.pdf" target="_blank">$162.8 million,&nbsp;</a>SNDL (NASDAQ:<a href="https://investorplace.com/stock-quotes/sndl-stock-quote/">SNDL</a>) marked a considerable uplift in operating performance. This loss was based on (partially) restructuring and goodwill impairment. However, it is<a href="https://s201.q4cdn.com/372870431/files/doc_earnings/2023/q4/presentation/SNDL-Q4-2023-Corporate-Presentation.pdf" target="_blank">&nbsp;up 53% from 2022&rsquo;s loss</a>&nbsp;of $347.8 million, which signifies a solid move towards a complete turnaround. Likewise, in Q4 2023, the operating loss was $84.9 million. Again, this is a 45% improvement from Q4 2022 ($154.6 million loss).



Similarly, in 2023, adjusted EBITDA from continuing operations was&nbsp;<a href="https://s201.q4cdn.com/372870431/files/doc_earnings/2023/q4/transcript/final-sndl-inc-q4-2023-results.pdf" target="_blank">$29.2 million</a>. This is a solid increase over 2022&rsquo;s deficit of $15.8 million. Furthermore, adjusted EBITDA from continuing operations improved drastically by 147% to $3.5 million in Q4 2023 from Q4 2022.



Fundamentally, these gains in operational performance suggest SNDL&rsquo;s focus on margin expansion, cost reduction, and operational edge. Overall, by improving its operating performance, SNDL can achieve sustainable growth, optimize its bottom line, and build long-term value.



<h2>Puma Biotechnology (PBYI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/cancer-300x169.jpg" alt="A variety of pills, pill bottles, and droppers arranged on a table in multiple bright colors."><div>Source: Shutterstock</div></div>Puma Biotechnology (NASDAQ:<a href="https://investorplace.com/stock-quotes/pbyi-stock-quote/">PBYI</a>) has constantly increased, with slight product and net&nbsp;revenue swings. This includes revenue from sales of NERLYNX. Similarly, product revenue for 2023 was $203.1 million, stable annually. The annual comparison shows a slight growth in product revenue. 



Indeed, this expansion suggests that there is still a market lead for Puma Biotechnology&rsquo;s <a href="https://s24.q4cdn.com/201644000/files/doc_earnings/2023/q4/presentation/Puma-Q4-23-Commercial-Slides-Final.pdf" target="_blank">main product, NERLYNX</a>, which is crucial to the company&rsquo;s total earnings. Moreover, Puma Biotechnology derives top-line from royalties in addition to product sales. This adds to the stability of its consolidated revenue. Royalty revenue for&nbsp;<a href="https://finance.yahoo.com/news/puma-biotechnology-inc-nasdaq-pbyi-132935557.html" target="_blank">2023 was $32.5 million</a>, uplifted from $28.0 million in 2022. 



To conclude, Puma Biotechnology&rsquo;s top-line solidity is intensified by the stability of royalty revenue, balancing with the boost in product sales.



<h2>Granite Ridge (GRNT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/03/oilandgasstocks1600-300x169.png" alt="Panorama of Oil and Gas central processing platform in twilight, offshore hard work occupation twenty four working hours. Best oil stocks to buy"><div>Source: Oil and Gas Photographer / Shutterstock.com</div></div>Solid performance during Q4 and 2023 indicates Granite Ridge&rsquo;s (NYSE:<a href="https://investorplace.com/stock-quotes/grnt-stock-quote/">GRNT</a>) high boost in output. Compared to Q4 2022, <a href="https://s202.q4cdn.com/863234614/files/doc_financials/2023/q4/Granite-Ridge-Resources-Inc-Reports-Fourth-Quarter-and-Full-Year-2023-Results-and-Provides-Outlook-for-2024-2024.pdf" target="_blank">production increased by 18%&nbsp;</a>to over 26K barrels of oil equivalent (Boe) per day. In particular, oil output rose 8% to 12.28K barrels per day. Natural gas output increased by 29% to over 82.5K thousand cubic feet (Mcf) per day.



In 2023, total production boosted by&nbsp;<a target="_blank" href="https://s202.q4cdn.com/863234614/files/doc_financials/2023/q4/Granite-Ridge-Resources-Inc-Reports-Fourth-Quarter-and-Full-Year-2023-Results-and-Provides-Outlook-for-2024-2024.pdf">23% to 24,311 Boe</a>&nbsp;per day compared to 2022. Oil production increased by 14% to 11.4K barrels. Natural gas output increased considerably by&nbsp;<a target="_blank" href="https://finance.yahoo.com/news/granite-ridge-resources-inc-nyse-123352999.html">32% to 77.4K</a>&nbsp;Mcf per day. Granite Ridge&rsquo;s exploration and extraction efforts have proven effective, as seen in a solid and rapid boost in output.&nbsp;



To sum up, these patterns show that the business may effectively access hydrocarbon reserves, which translates into a higher prospective income stream. Therefore, Granite Ridge&rsquo;s solid production increase puts it in a good position for future development and competitiveness in the market.



As of this writing, Yiannis Zourmpanos held a long position in SOFI. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.
<div>Yiannis Zourmpanos is the founder of Yiazou Capital Research, a stock-market research platform designed to elevate the due diligence process through in-depth business analysis.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/04/7-stocks-under-15-predicted-to-boom-in-the-next-2-years/">7 Stocks Under $15 Predicted to Boom in the Next 2 Years</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 Stocks Under $15 Predicted to Boom in the Next 2 Years

AISP

BITF

CMPO

COIN

GMAB

GRNT

IFBD

MDAI

MIRO

NKGN

PIXY

SNDL

SOFI

SWIN

UTHR

VHAI

VTGN

Press Releases

Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference

Opinion

Thinking about buying stock in Marpai, Phunware, Spirit Airlines, BigBear.ai, or Puma Biotechnology?